Positionally cloned genes and age-specific effects in asthma and atopy: an international population-based cohort study (ECRHS)

F Castro-Giner, R de Cid, J R Gonzalez, D Jarvis, J Heinrich, C Janson, E R Omenas, M C Matheson, I Pin, J M Antó, X Estivill, M Kogevinas

ABSTRACT

Several genes identified by positional cloning have been associated with asthma and atopy, but no point mutations have been replicated. Age at onset of asthma has been associated with different phenotypic characteristics, and with variants at chromosome 17q21 identified through genome-wide association. This study examined the associations and age-specific effects on asthma, atopy and bronchial hyper-responsiveness (BHR) of five candidate genes previously identified by positional cloning (ADAM33, PHF11, NPSR1, DPP10, SPINK5).

Methods 51 polymorphisms from 2474 participants from 13 countries who took part in the European Community Respiratory Health Survey (1990–2000) were studied. Asthma and age at onset of asthma were assessed by questionnaire data, BHR by methacholine challenge and atopy by specific immunoglobulin E to four common allergens.

Results Significant associations with asthma, atopy and particularly for asthma with atopy were observed for a large region of 47 kb in the NPSR1 gene, even after Bonferroni correction for multiple comparisons (p<0.001). The associations with NPSR1 were stronger in those reporting a first attack of asthma before the age of 15, with statistically significant interactions with age of onset found for three SNPs. The evidence for ADAM33 and BHR and for an age-specific effect of two SNPs in DPP10 and asthma was weaker.

Conclusion This study provides further evidence for an effect of NPSR1 on asthma, atopy and atopic asthma. In addition, this analysis suggests a role for NPSR1 in early-onset asthma driven by the strong effect of this gene on atopic asthma.

Asthma is a complex disease which shows phenotypic heterogeneity and is related with atopy, bronchial hyper-responsiveness (BHR) and increased immunoglobulin E (IgE) levels. Linkage analysis followed by positional cloning has been a powerful design to identify the genetic basis of asthma. Eight susceptibility genes to asthma, BHR or atopy have been identified by this technique, although their function remains unclear. ADAM metallopeptidase domain 33 (ADAM33) on chromosome 20p was initially identified as an asthma and BHR susceptibility gene. Neuropeptide S receptor 1 (NPSR1, also known as GPRA or GPR154), which is located on chromosome 7p, encodes a G-protein-coupled receptor that is upregulated in epithelial cells in inflamed airways and was initially identified as an asthma and atopy-related gene. PDE5 finger protein 11 (PHF11) on chromosome 15 was reported as a gene associated with atopy and total IgE. Dipetidyl-peptidase 10 (DPP10) located on chromosome 2q may modulate the activity of various proinflammatory and regulatory chemokines and cytokines, and could also be important in neural regulation of smooth muscle tone. Serine protease inhibitor kazal type 5 (SPINK5, chromosome 5q) encodes a protease inhibitor protein and was identified as a gene involved in high serum IgE levels and atopic manifestations. Other genes identified by positional cloning are HLA-G histocompatibility antigen class I G (HLA-G), cytoplasmatic FMR1-interacting protein 2 (CYFIP2), prostanoid DP receptor (PTGDR) and interleukin-1 receptor antagonist (IL1RN). Studies on these candidate genes have not always replicated the initial findings.

Longitudinal studies have shown that age at onset of asthma is associated with differences in phenotypic characteristics. Information on age at onset may help to identify genetic determinants and understand the underlying pathophysiology that contributes to particular phenotypes. Bouzigon et al recently reported that the risk of asthma conferred by 17q21 variants is restricted to early-onset asthma. Only one recent study has evaluated whether a similar pattern by age at onset occurs for asthma genes identified by positional cloning.

The aim of this study is to replicate genetic associations with asthma, BHR and atopy and to identify age-specific effects of five candidate genes previously identified by positional cloning (ADAM33, PHF11, NPSR1, DPP10, SPINK5) using data from a large international population-based cohort (the European Community Respiratory Health Survey, ECRHS).

METHODS

The methodology of the ECRHS has been described elsewhere. Briefly, the ECRHS is a random population-based multicentre cohort of subjects aged 20–44 years at time of recruitment (1990, ECRHS I) and then followed up approximately 10 years later (ECRHS II). Subjects completed a long questionnaire on respiratory symptoms and underwent a clinical evaluation including lung function, atopy and bronchial responsiveness. A complementary sample of...
subjects with asthma symptoms at recruitment was also included in the study and followed up.

The presence of asthma was based on a positive response to one of two questions: attack of asthma during the 12 months preceding the interview or current use of asthma medication. Most patients with asthma defined by these two questions (93%) also reported a doctor diagnosis of asthma. Age at onset of asthma was assessed by the question “How old were you when you had your first attack of asthma?” The long-term reliability of this question was reported to be high in the ECRHS. Since analyses of other studies have defined asthma as a report of “doctor diagnosed asthma”, we also used this definition in an alternative analysis. BHR was defined as a 20% fall in forced expiratory volume in 1 s (FEV1) from the highest FEV1 post-diluent value during methacholine challenge with an accumulated dose of 1 mg. Specific IgE levels to four common aeroallergens (cat, timothy grass, Dermatophagoides pteronyssinus and Cladosporium herbarum) were measured with the Pharmacia CAP system (Pharmacia Diagnostics, Uppsala, Sweden). Atopy was defined as sensitisation (specific IgE levels >0.35 kU/l) to any allergen.

In order to increase the accuracy of the classification of asthma, we considered subjects as cases if they reported any of the three mentioned traits both at baseline (ECRHS I) and at follow-up (ECRHS II). Our comparison group included all subjects who had negative tests for atopy or BHR or who did not report ever having had asthma at both stages of the ECRHS. In addition, subjects recruited in the symptomatic sample (and who did not qualify as cases) were also excluded from the comparison group. Figure 1 shows the selection process of subjects in the ECRHS study and those available for the present analysis.

A description of the selection and genotyping of single nucleotide polymorphisms (SNPs) is given in the online supplement and the SNPs examined are listed in table 1 in the online supplement. SNPs were genotyped using the SNFlex platform (Applied Biosystems, Foster City, California, USA) according to the manufacturer’s instructions.

**Statistical analysis**

Analyses were adjusted for country, body mass index, smoking status and sex. The analysis of single marker effects was performed assuming an additive genetic model, considering the most frequent allele as the reference category and using logistic regression analysis implemented in the SNPassoc package Version 1.5–1 from R Statistical Software Version 2.6.1 (R Foundation for Statistical Computing, Vienna, Austria, 2007). To correct for multiple comparisons, we applied a Bonferroni correction for the 51 independent loci genotyped (significant p = 0.001). Haplotypes were estimated using haplo.em function from haplo.stats package Version 1.3.8. D, r² and χ² p values for marker independence were estimated to determine linkage disequilibrium between genetic markers. We used a sliding window approach to construct haplotypes in windows up to four adjacent SNPs using the haplo.score.slide command from HaploStats package. The population attributable risk (PAR) for haplotypes was calculated from the odds ratios (ORs) using the formula PAR = 100 × P × [OR – 1]/[P × (OR – 1) + 1], where P is the prevalence of the haplotype in the population.

---

**Figure 1** Flow chart showing the selection process and numbers of subjects available for analysis.

Definitions for asthma, atopy and bronchial hyper-responsiveness (BHR) are specified in the Methods section. ECRHS, European Community Respiratory Health Survey.
We identified the most appropriate cut-off for age at onset of asthma following a modification of the method described by Bouzigon et al.\textsuperscript{14} For each specific age from 1 to 40 years, associations between genetic polymorphisms and asthma were assessed by multinomial regression analyses stratifying cases using the specific age at onset of asthma as a cut-off (0 = control; 1 = onset of asthma on or before specific age; 2 = onset of asthma after specific age). By using this model we compared each group of cases with the whole set of non-asthmatic individuals. Tests for linear trend of OR were calculated using the categorised variable quantitatively after assigning a linear score to each ordered category. We then identified the age at onset for which the p value of interaction between the polymorphisms and age at onset was maximum. Interaction was assessed using the likelihood ratio test by comparing the models with and without the interaction term.

Population stratification analysis of the ECRHS was assessed using a set of ancestry-informative markers in addition to oculocutaneous albinism II (OCA2) and lactase (LCT).\textsuperscript{21, 22} Genomic control\textsuperscript{23} and principal component analysis using EIGENSTRAT\textsuperscript{24} (see figure 1 in online supplement) fail to evidence population stratification.

Additional information on material and methods can be found in the online supplement.

RESULTS

The characteristics of the population are shown in table 1. Our analysis was restricted to 4531 subjects of ECRHS II whose DNA was available and who had a genotyping rate over 80% (mean 98.5%) and complete evaluation on asthma, atopy and BHR (figure 1). The prevalence of asthma was 7.4% (n = 320), of atopy 24.5% (n = 1060) and of BHR 6.2% (n = 267). Overlapping between these three phenotypes is shown in figure 2. The comparison set was restricted to the 1215 subjects (28.0%) who fulfilled the a priori criteria. Only one SNP (rs765023) was found to deviate from Hardy-Weinberg equilibrium in the comparison group (p < 0.01, see table 2 in online supplement).

Significant associations (nominal p value ≤ 0.05) with asthma, atopy and BHR are summarised in table 2. Nominally significant associations for asthma (six SNPs) or atopy (eight SNPs) were observed only for the NPSR1 gene. Multiple test correction (Bonferroni p = 0.001) yielded three SNPs associated with asthma (rs184448, rs524957, rs524981) and one with atopy (rs524956). For BHR, one significant association was found with a polymorphism of the ADAAA33 gene (rs2787095), although this did not pass Bonferroni correction (p = 0.04). Complete information for all the evaluated polymorphisms is shown in table 3 in the online supplement.

To exclude possible overlapping effects of asthma and atopy, we evaluated in a stratified analysis (figure 3) those NPSR1 SNPs more strongly associated with either atopy or asthma (p value for any of two outcomes < 0.01, see table 2). To evaluate these effects we compared ORs for each subgroup. Independent effects were observed for both atopy and asthma but, mainly, a joint effect was seen with the highest ORs in subjects with both atopy and asthma (figure 3).

Multiple marker analysis was performed in those genes that showed significant associations in the single marker analysis. In NPSR1 we identified three blocks with high linkage disequilibrium (see figure 2 in the online supplement), one of 6 kb, one of 12 kb and a large block of 47 kb which contains the risk polymorphisms identified for asthma and atopy (table 2). Through haplotype sliding windows analysis (table 3), we identified a four marker region in the 47 kb block of the NPSR1 gene (rs184448, rs524956, rs524957, rs524960) significantly associated with asthma (p = 0.001), atopy (p = 0.001) and atopic asthma (p = 0.004). One of the SNPs previously identified in the single marker analysis for asthma was not in this block (rs524981). However, this polymorphism is in strong linkage disequilibrium with three of these four markers (D’ > 0.95, r² > 0.60, $\chi^2$ p value < 2 × 10\textsuperscript{-15}). The PAR for this haplotype was 9.15% for asthma, 6.05% for atopy and 9.75% for the combination of asthma and atopy.

Additional analyses using different outcome definitions supported these findings (see table 5 in online supplement). A less restrictive definition of asthma was defined as subjects

\begin{table}
\centering
\begin{tabular}{lcc}
\hline
Variable & Total population (n = 4331) & Population in this analysis (n = 2474) \\
\hline
Country & & \\
Australia & 341 (7.9\%) & 239 (9.7\%) \\
France & 549 (12.7\%) & 330 (13.3\%) \\
Germany & 439 (10.1\%) & 256 (10.3\%) \\
Norway & 436 (10.1\%) & 254 (10.3\%) \\
Spain & 1165 (26.9\%) & 571 (23.1\%) \\
Sweden & 643 (14.8\%) & 414 (16.7\%) \\
Switzerland & 400 (9.2\%) & 202 (8.2\%) \\
UK & 358 (8.3\%) & 208 (8.4\%) \\
Sex & & \\
Men & 2089 (48.2\%) & 1271 (51.4\%) \\
Women & 2242 (51.8\%) & 1203 (48.6\%) \\
Smoking & & \\
Never & 1855 (42.8\%) & 1124 (45.4\%) \\
Ex & 1144 (26.4\%) & 670 (27.1\%) \\
Current & 1348 (31.1\%) & 692 (28\%) \\
Mean (SD) age (years) & 42.8 (7.2) & 42.4 (7.1) \\
Comparison group & & \\
Asthma & 320 (7.4\%) & 1124 (45.4\%) \\
Atopy & 1060 (24.5\%) & 1203 (48.6\%) \\
Atopic asthma & 195 (4.5\%) & 195 (7.9\%) \\
Non-atopic asthma & 55 (1.3\%) & 55 (2.2\%) \\
Atopy in non-asthmatics & 865 (20\%) & 865 (35\%) \\
BHR & 287 (6.2\%) & 267 (10.8\%) \\
Other* & 1307 (30.2\%) & 422 (17.1\%) \\
\hline
\end{tabular}
\caption{Characteristics of population (includes cases and subjects from the comparison group and cases)}
\end{table}
Table 2 Nominal significant associations (p < 0.05) between single nucleotide polymorphisms (SNPs) and persistent asthma, persistent atopy and persistent bronchial hyper-responsiveness (BHR) under the additive genetic model

<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP</th>
<th>Asthma</th>
<th>Atopy</th>
<th>BHR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>p Value</td>
<td>OR (95% CI)</td>
<td>p Value</td>
</tr>
<tr>
<td>ADAM33</td>
<td>rs2787095</td>
<td>1.06</td>
<td>0.87 (1.29)</td>
<td>0.5043</td>
</tr>
<tr>
<td>NPSR1</td>
<td>rs714588</td>
<td>1.04</td>
<td>0.86 (1.27)</td>
<td>0.6709</td>
</tr>
<tr>
<td>NPSR1</td>
<td>rs1345267</td>
<td>1.61</td>
<td>0.66 (1.00)</td>
<td>0.0036</td>
</tr>
<tr>
<td>NPSR1</td>
<td>rs194448</td>
<td>1.48</td>
<td>1.20 (1.02)</td>
<td>0.0002</td>
</tr>
<tr>
<td>NPSR1</td>
<td>rs324936</td>
<td>1.21</td>
<td>0.97 (1.51)</td>
<td>0.0868</td>
</tr>
<tr>
<td>NPSR1</td>
<td>rs324957</td>
<td>1.41</td>
<td>1.15 (1.74)</td>
<td>0.001</td>
</tr>
<tr>
<td>NPSR1</td>
<td>rs324960</td>
<td>0.74</td>
<td>0.60 (0.93)</td>
<td>0.008</td>
</tr>
<tr>
<td>NPSR1</td>
<td>rs324981</td>
<td>0.69</td>
<td>0.56 (0.85)</td>
<td>0.0004</td>
</tr>
<tr>
<td>NPSR1</td>
<td>rs325462</td>
<td>0.76</td>
<td>0.62 (0.93)</td>
<td>0.0085</td>
</tr>
</tbody>
</table>

Model adjusted by country, body mass index, age, sex and smoking status.

Table 3 Haplotype analysis of NPSR1 with sliding windows

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Window size</th>
<th>Best global p value</th>
<th>Loci</th>
<th>Best individual p value</th>
<th>Best individual haplotype</th>
<th>OR (95% CI)</th>
<th>PAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td>2</td>
<td>0.0005</td>
<td>10, 11</td>
<td>0.0004</td>
<td>GC (15%)</td>
<td>1.66 (1.25 to 2.21)</td>
<td>9.01</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.002</td>
<td>10, 11, 12</td>
<td>0.002</td>
<td>GCA (15%)</td>
<td>1.57 (1.18 to 2.10)</td>
<td>7.88</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>0.001</td>
<td>10, 11, 12, 13</td>
<td>0.001</td>
<td>GCAC (15%)</td>
<td>1.67 (1.22 to 2.29)</td>
<td>9.13</td>
</tr>
<tr>
<td>Atopy</td>
<td>2</td>
<td>0.004</td>
<td>10, 11</td>
<td>0.001</td>
<td>GT (30%)</td>
<td>1.27 (1.10 to 1.46)</td>
<td>7.49</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.012</td>
<td>10, 11, 12</td>
<td>0.0012</td>
<td>GTA (30%)</td>
<td>1.26 (1.10 to 1.45)</td>
<td>7.23</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>0.019</td>
<td>10, 11, 12, 13</td>
<td>0.001</td>
<td>GTAC (28%)</td>
<td>1.23 (1.11 to 1.53)</td>
<td>6.05</td>
</tr>
<tr>
<td>Atopic asthma</td>
<td>2</td>
<td>0.0007</td>
<td>10, 11</td>
<td>0.001</td>
<td>GC (15%)</td>
<td>1.78 (1.26 to 2.51)</td>
<td>10.47</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.006</td>
<td>10, 11, 12</td>
<td>0.004</td>
<td>GCA (15%)</td>
<td>1.68 (1.18 to 2.35)</td>
<td>9.01</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>0.0003</td>
<td>10, 11, 12, 13</td>
<td>0.004</td>
<td>GCAC (15%)</td>
<td>1.72 (1.19 to 2.51)</td>
<td>9.75</td>
</tr>
</tbody>
</table>

Model adjusted by country, body mass index, age, sex and smoking status. Locus 10: rs184448; locus 11: rs324936; locus 12: rs324957; locus 13: rs324960. PAR, population attributable risk.

DISCUSSION

This study confirms the association of NPSR1 gene with atopy and asthma, and identifies for the first time that the effect of NPSR1 on asthma could be age-dependent, being stronger for asthma with onset at early ages. Weaker evidence was observed for an age-specific effect of DPP10 on asthma. In addition, we reported a weak association between ADAM33 and BHR that did

reporting asthma in either of the two contacts. The same analysis was done for atopy. The results support the effects observed for permanent phenotypes (i.e., subjects reporting outcomes in both cohorts), with the most significant effects on asthma and atopy observed for the SNPs located in the second haplotype block. An additional analysis for “physician diagnosed asthma” showed the same pattern of associations as those observed for the main analyses.

We then investigated age-specific effects for these genetic variants. Multinomial logistic regression for each cut-off of age at onset was performed for the six significant SNPs for asthma (see figure 3 in online supplement). A significant interaction was observed for SNPs rs324981 and rs325462 for age at onset between 9 and 14 years. For rs324981 (figure 4a), the maximum p value was observed for a cut-off at age 14 (p for interaction = 0.01), while for rs325462 it was at age 10 (p for interaction = 0.02). The cut-off was set at the maximum age for which interaction was significant (14 years). From the 320 individuals reporting persistent asthma, 141 reported the first attack of asthma before the age of 14 and 146 after the age of 14. Eleven subjects did not report age at onset in both surveys and 24 had different categories between the two surveys and were therefore excluded from the analysis of age at onset. The strength of the association (OR) between these NPSR1 polymorphisms and asthma was more pronounced in patients with early-onset asthma (≤14 years, table 4). The analysis for the remaining NPSR1 polymorphisms (see table 6 in online supplement) showed a significant interaction for another NPSR1 variant, rs324931 (p for interaction = 0.05), with a pattern of association according to age at onset similar to the two above NPSR1 SNPs (OR 0.66 for early-onset asthma and OR 0.86 for late-onset asthma). Differences in the prevalence of atopy were observed between early-onset and late-onset asthma (75% vs 49%).

Asthma and atopy are strongly correlated in children. The evaluation of age-specific effects for atopic asthma did not show significant interactions for the rs324981 SNP (figure 4b) or the remaining NPSR1 SNPs (data not shown). The stratified analysis using the cut-off age of 14 years (table 4) shows that the association of these variants with early-onset asthma is similar in atopic asthma to that in general asthma. Overall, the effect for late-onset asthma is increased for atopic asthma, narrowing the differences between early and late onset of asthma.

The evaluation of age at onset of asthma using the cut-off at age 14 years for the other genes (see table 6 in online supplement) shows significant interactions for two polymorphisms in the DPP10 gene, rs1430090 (OR 0.81 for early-onset asthma vs OR 1.17 for late-onset asthma, p for interaction = 0.04) and rs104096456 (OR 0.85 for early-onset asthma vs OR 1.36 for late-onset asthma, p for interaction = 0.05), although the effect of these polymorphisms was not significant in either early-onset or late-onset asthma.

This study confirms the association of NPSR1 gene with atopy and asthma, and identifies for the first time that the effect of NPSR1 on asthma could be age-dependent, being stronger for asthma with onset at early ages. Weaker evidence was observed for an age-specific effect of DPP10 on asthma. In addition, we reported a weak association between ADAM33 and BHR that did
not pass Bonferroni correction. No statistically significant associations were found for PHF11 and SPINK5. The failure to replicate can be caused by several factors such as phenotype heterogeneity, small sample size, different populations and population stratification. PHF11 was initially reported as a gene associated with total IgE and asthma. We failed to replicate the results for asthma and atopy, although we evaluated specific IgE instead of IgE levels. Only one replication study reported a weak association with asthma. SPINK5 was associated with high serum IgE levels and atopic manifestations, and replication studies have confirmed these findings. To date, only two studies have evaluated the association with asthma and reported inconsistent findings.

Our results support previous evidence for the role of NPSR1 in asthma and atopy and, in addition, suggest that the effect is stronger for the combination of asthma and atopy. The NPSR1 gene was identified by positional cloning as an asthma and atopy (high IgE levels) susceptibility gene. While some subsequent studies have replicated this finding in asthma, atopy (high serum IgE) or allergic symptoms, other studies did not find a significant effect. The similar effect on asthma and atopy was observed in the initial study and in most further replication studies. The effect on the combination of asthma and atopy (allergic asthma) has also been reported by previous studies.

Polymorphisms of NPSR1 significantly associated with asthma and atopy in this study are located in the region comprising intron 2, exon 3 and intron 3. This region is within the same 135 kb genomic segment identified by positional cloning as a susceptibility locus for asthma-related phenotypes. Among these polymorphisms, only the rs324981 (located in the exon 3) is a non-synonymous substitution, resulting in an amino acid replacement in the protein. This change is located in the first exoloop of the putative ligand-binding protein and produces a gain of function, increasing the intrinsic efficacy (the ability of neuropeptide S to activate the receptor) as well as intracellular

Figure 3  Odds ratios (bars) and 95% confidence intervals (lines) for the stratified analysis of the combinations of atopy and asthma for selected NPSR1 polymorphisms. The logistic regression model was adjusted by country, body mass index, age, sex and smoking status. Exact values for odds ratios, confidence intervals and p values can be found in table 4 in the online supplement.
trafficking of the receptor to the cell membrane. Association of the other polymorphisms (mainly located in the second intron) may be explained by an effect on alternative splicing or linkage with an untested variant.

The age of asthma onset may differentiate phenotypic characteristics. We identified a cut-off point for age at onset at 14 years. This cut-off point is consistent with the age of puberty, and a similar age has been used in previous studies for discerning childhood and adult asthma. Early-onset asthma is more likely to be linked to a family history of asthma, an indicator of a stronger genetic component, and is a more homogeneous disease, both of which increase the probability of identifying genetic effects. The stronger effects of NPSR1 in early-onset asthma suggest that the pathophysiological mechanisms may vary according to age. In children, asthma is strongly correlated with atopy. We have shown that the effect of NPSR1 is stronger for atopic asthma and, in addition, the differences between early-onset and late-onset asthma disappeared when atopic asthma was evaluated. This suggests that the stronger effects observed at early ages are due to an effect of these genes on atopic asthma. The putative role of NPSR1 in the modulation of innate immunity and its implication in atopic sensitisation supports the hypothesis that this gene could be more closely linked to early-onset asthma than to adult asthma through its implication in atopic asthma. Recent work found that NPSR1 may modulate the effect of farm exposure in allergic symptoms in children. Although previous studies have reported an effect of NPSR1 polymorphisms in both childhood and adult asthma, our study is the first to discern the role of NPSR1 by age of onset. We also observed an interaction between age at onset and two polymorphisms in DPP10. The lack of a significant association of these variants with asthma, however, makes interpretation of the interaction difficult. A recent analysis conducted on the British 1958 birth cohort showed that, similar to our study, the

Table 4  Multinomial analysis of age at onset of asthma and NPSR1 SNPs under the additive genetic model

<table>
<thead>
<tr>
<th>SNP</th>
<th>OR (95% CI)</th>
<th>p Value</th>
<th>OR (95% CI)</th>
<th>p Value</th>
<th>p Value interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1345267</td>
<td>0.83 (0.62 to 1.12)</td>
<td>0.2163</td>
<td>0.77 (0.58 to 1.02)</td>
<td>0.0655</td>
<td>0.5927</td>
</tr>
<tr>
<td>rs184448</td>
<td>1.71 (1.26 to 2.32)</td>
<td>0.0005</td>
<td>1.36 (1.03 to 1.78)</td>
<td>0.0281</td>
<td>0.1604</td>
</tr>
<tr>
<td>rs324957</td>
<td>1.75 (1.29 to 2.35)</td>
<td>0.0003</td>
<td>1.27 (0.97 to 1.67)</td>
<td>0.0850</td>
<td>0.0674</td>
</tr>
<tr>
<td>rs324960</td>
<td>0.64 (0.46 to 0.88)</td>
<td>0.0067</td>
<td>0.79 (0.59 to 1.05)</td>
<td>0.1070</td>
<td>0.1431</td>
</tr>
<tr>
<td>rs324981</td>
<td>0.54 (0.40 to 0.74)</td>
<td>0.0001</td>
<td>0.81 (0.62 to 1.06)</td>
<td>0.1331</td>
<td>0.0134</td>
</tr>
<tr>
<td>rs325462</td>
<td>0.60 (0.44 to 0.81)</td>
<td>0.0007</td>
<td>0.86 (0.66 to 1.13)</td>
<td>0.2786</td>
<td>0.0243</td>
</tr>
<tr>
<td>Atopic asthma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1345267</td>
<td>0.87 (0.62 to 1.12)</td>
<td>0.2163</td>
<td>0.66 (0.45 to 0.97)</td>
<td>0.0348</td>
<td>0.3142</td>
</tr>
<tr>
<td>rs184448</td>
<td>1.69 (1.20 to 2.38)</td>
<td>0.0025</td>
<td>1.45 (1.00 to 2.10)</td>
<td>0.0481</td>
<td>0.2887</td>
</tr>
<tr>
<td>rs324957</td>
<td>1.72 (1.23 to 2.40)</td>
<td>0.0015</td>
<td>1.46 (1.01 to 2.11)</td>
<td>0.0469</td>
<td>0.314</td>
</tr>
<tr>
<td>rs324960</td>
<td>0.66 (0.46 to 0.94)</td>
<td>0.0203</td>
<td>0.88 (0.60 to 1.28)</td>
<td>0.4957</td>
<td>0.0765</td>
</tr>
<tr>
<td>rs324981</td>
<td>0.59 (0.42 to 0.83)</td>
<td>0.002</td>
<td>0.72 (0.50 to 1.04)</td>
<td>0.0806</td>
<td>0.181</td>
</tr>
<tr>
<td>rs325462</td>
<td>0.61 (0.44 to 0.84)</td>
<td>0.003</td>
<td>0.76 (0.53 to 1.09)</td>
<td>0.1398</td>
<td>0.1683</td>
</tr>
</tbody>
</table>

Model adjusted by country, body mass index, age, sex and smoking status.

Figure 4  p Values for interaction from the multinomial logistic regression for each cut-off of age at onset and the rs324981 SNP from NPSR1 for (a) asthma and (b) atopic asthma. Dotted lines indicate the nominal p value (0.05). Model adjusted by country, body mass index, age, sex and smoking status.
effect of DPP10 was specific for asthma onset after the age of 17 years, while they did not observe an effect of NPSR1. This study differs in the main outcome of asthma used because it included wheezing in the definition of asthma.

Our results indicate an effect of ADAM33 on BHR. Although the significance of this association was weak (p = 0.04) and did not pass Bonferroni correction, other studies have also reported this association (reviewed by Hersh et al).23 These findings support the hypothesis that ADAM33 is more related to airway wall remodelling rather than being restricted to asthma.24

Despite the strong evidence for NPSR1 reported in this study, several issues in the interpretation of the findings should be considered. The first is related to the international nature of the ECRHS cohort and a potential concern for population stratification. Previous analysis in the ECRHS has shown little evidence of population stratification, but the number of markers evaluated could be insufficient.22 Even though there is only a low level of genetic variation among Europeans, there is some relation between genetic and geographical distances.41 To take into account this limitation, all the analyses were adjusted by country.

Another issue is related to phenotype definition. For this analysis we selected persistent traits at the time of evaluation to have a more reliable evaluation of the phenotypes. This implies that, irrespective of age at onset, all had asthma in adulthood. Persistence of asthma from childhood to adulthood could be related to a different phenotype of asthma than that occurring in childhood and not recurring later. Longitudinal cohort studies have shown that patients with persistent asthma have a higher prevalence of allergic sensitisation, airway responsiveness, lower lung function and more severe asthma in childhood than those in whom asthma did not persist.33 42 We have already discussed the strong association of NPSR1 with atopic asthma, but we cannot exclude the possibility that this could also be due to an effect of this gene on other specific phenotypes such as more severe asthma.

Multiple testing is an important source of false positive results. In the analysis of the genetic main effects we considered a Bonferroni correction by the number of SNPs tested and not by the number of outcomes assessed since there is a high correlation among the phenotypes. Some polymorphisms from NPSR1 remained significant after Bonferroni correction, which highlights the strength of this association. However, the Bonferroni test is over-conservative since polymorphisms within a gene are not completely independent and selection of the genes was based on strong pre-established hypotheses. For these reasons, the reported association between ADAM33 and BHR using a threshold p value of 0.05 may be considered as a positive replication. In the analysis of the interaction with age at onset, we also applied a threshold p value of 0.05 because the a priori statistical power to detect an interaction with age at onset was relatively low.43 These results should therefore be interpreted with caution.

In conclusion, this study gives independent support to NPSR1 as a risk factor for asthma, atopy and atopic asthma. In addition, this analysis adds evidence to the importance of considering age-specific effects in evaluating the genetic risk factors in asthma, suggesting a role for NPSR1 in early-onset asthma driven by the strong effect of this gene on atopic asthma. To a less extent, this study replicates previous evidence for the role of ADAM33 on BHR and suggests an age-specific effect of DPP10 on asthma.

Author affiliations. 1Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain 2Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain 3CIBER Epidemiologı´a y Salud Puxblica (CIBERESP), Barcelona, Spain 4Genes and Disease Program, Center for Genomic Regulation, Barcelona, Spain 5Respiratory Epidemiology and Public Health Group, National Heart and Lung Institute, Imperial College, London, UK 6Institute of Epidemiology, Helmholtz Zentrum Munchen, Munich, Germany 7Department of Medical Sciences, Respiratory Medicine and Allergology, Uppsala University, Uppsala, Sweden 8Institute of Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway 9Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway 10Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Victoria, Australia 11Inserm, US23, Centre de Recherche Albert Bonniot, Immunologie et Immunothérapie des cancers, La Tronche, France 12University Joseph Fourier, Grenoble, France 13Centre Hospitalier Universitaire de Grenoble, Grenoble, France 14Department of Health and Experimental Sciences, University Pompeu Fabra, Barcelona, Spain 15German Research Center for Environmental Health, Helmholtz Centre GSF, Munich, Germany 16National School of Public Health, Athens, Greece Funding This work was supported by grants from the MaratoTV3, Catalonia, Spain and Genome Spain. Additional funding was available in each research centre for data collection.

Competing interests None.

Ethics approval Ethical approval was obtained for each centre from the appropriate institutional ethics committee and written consent was obtained from each participant.

ECRHS List of Principal Investigators and Senior Scientific Team (members of the ECRHS Steering Committee in italics): Australia: Melbourne (M Abramson, R Woods, E H Walters, F Thien, G Benke); France: Paris (F Neukirch, B Leynaud, R Liard, M Zureik), Grenoble (I Pin, J Ferran-Quentini); Germany: Erfurt (U Heinrich, M Wijst, C Frye, I Meyer); Norway: Bergen (A Gulsvik, E Omenaas, C Svanes, B Laserum); Spain: Barcelona (J M Anto´, J Sunyer, M Kogevinas, J P Zock, X Basagana, A Jaen, F Burgos), Huelva (J Maldonado, A Pereira, J L Sanchez), Albacete (J Martinez-Moratalla Revira, E Almar), Galdakao (N Muniozguen, I Urritia), Odessa (F Payo); Sweden: Uppsala (C Janson, G Boman, D Norbach, M Gummnordsdotter), Umea (E Normann, M Soderberg, K Franklin, B Lundback, B Forsberg, I Nystrom); Switzerland: Basel (N Kindi, B Dibbert, M Hazenkamp, B Brutsche, U Ackermann-Liebrich); UK: London (P Burney, S Chinn, D Jarvis), Norwich (D Jarvis, B Harrison), Ipswich (D Jarvis, R Hall, D Seaton).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Positionally cloned genes and age-specific effects in asthma and atopy: an international population-based cohort study (ECRHS)

F Castro-Giner, R de Cid, J R Gonzalez, D Jarvis, J Heinrich, C Janson, E R Omenaas, M C Matheson, I Pin, J M Antó, M Wjst, X Estivill and M Kogevinas

Thorax 2010 65: 124-131 originally published online December 8, 2009
doi: 10.1136/thx.2009.119628